Clinical Research Of The Efficacy Of Buzhongyiqi Tang In Treating Lung-spleen Qi Deficiency Advanced Non-Small Cell Lung Cancer

Research objective:By observing the clinical efficacy of buzhong yiqi decoction,it is verified that it can improve the quality of life of patients with advanced non-small cell lung cancer(NSCLC).Research methods:A total of 62 NSCLC patients were enrolled according to the inclusion and exclusion criteria,and were randomly included in the combined treatment group(31 cases)and chemotherapy group(31 cases).The chemotherapy group was treated with two-drug chemotherapy containing platinum,and the combined treatment group was treated with buzhong yiqi decoction combined with chemotherapy.21 d was one course of treatment and three courses of treatment were continued.Patients in both groups were given support and symptomatic treatment during treatment.KPS score,TCM syndrome score,short-term efficacy,progression-free survival(PFS)and hematological toxicity were observed.Results:KPS score: after treatment,the KPS score of NSCLC patients in both groups was higher than that before treatment(P<0.05),and the KPS score in the combined treatment group was higher than that in the chemotherapy group(P<0.05).TCM syndrome score: clinical symptoms of NSCLC patients in both groups were significantly improved(P<0.05),and there was no statistically significant difference in chest pain symptoms between the two groups after treatment(P>0.05).In terms of other symptoms,the combined treatment group was significantly improved compared with the control group(P<0.05).Short-term efficacy: the effective rate was 35.48% in the combined treatment group and29.03% in the chemotherapy group,with no statistically significant difference(P>0.05).PFS: 11.58 months in the combined treatment group,9.97 months in the chemotherapy group,11.00 months in the median PFS combined treatment group,and 10.00 months in the chemotherapy group.There was no significant difference between the two groups(P>0.05).Hematological toxicity: there was a significant difference in WBC and HGB decline between the two groups after chemotherapy(P<0.05),and no statistical difference was found in the decrease of PLT.Conclusion:After three courses of treatment,the combined treatment group significantly improved the KPS score of NSCLC patients,improved their clinical symptoms and reduced hematological toxicity,highlighting the great advantage of integrated traditional Chinese and western medicine in improving the quality of life of patients with advanced lung cancer.In terms of short-term efficacy and PFS,the combined treatment group was slightly improved,but it could not be considered that there was a difference between the two groups.